232 results
8-K/A
EX-10.6
TXMD
TherapeuticsMD Inc
22 Nov 11
Entry into a Material Definitive Agreement
12:00am
in the Collateral.
3. Termination of Security Interest. Upon the satisfaction of the payment in full of all Obligations, the security interest granted herein … shall terminate and all rights to the Collateral shall revert to the Debtor. Collateral Agent shall, upon such satisfaction, execute, acknowledge
8-K
EX-99.1
TXMD
TherapeuticsMD Inc
8 Jan 19
Regulation FD Disclosure
7:01am
patient satisfaction in clinical trials 1 ▪ Average daily release over one year of use: 0.15 mg/day segesterone acetate 0.013 mg/day ethinyl estradiol ▪ … or glucocorticoid effects at contraceptive doses ▪ Strong safety and efficacy data ▪ High patient satisfaction and acceptability ANNOVERA - 1 - Year Vaginal System
8-K
EX-10.2
TXMD
TherapeuticsMD Inc
21 Jun 12
Entry into a Material Definitive Agreement
12:00am
to Collateral Agent and grants to Collateral Agent a security interest in the Collateral.
3. Termination of Security Interest. Upon the satisfaction … to the Debtor.Collateral Agent shall, upon such satisfaction, execute, acknowledge, and deliver to the Debtor (a) an instrument in writing releasing
8-K
EX-10.11
TXMD
TherapeuticsMD Inc
18 Feb 11
Entry into a Material Definitive Agreement
12:00am
(the "Assignor"). This Assignment Agreement is made as part of Assignee's acceptance of collateral in full satisfaction of debt owed by Assignor to Assignee … by such mark, and
WHEREAS, in connection with the full satisfaction of a certain Secured Promissory Note from AMHN to Seatac dated December 16, 2010
8-K
EX-99.1
7osfxz75uf 68
15 Mar 13
TherapeuticsMD Announces Pricing of Public Offering of Common Stock
12:00am
8-K
cef6x3d
17 Apr 19
TherapeuticsMD Signs Binding Commitment Letter for $300 Million Non-Dilutive Term Loan Financing Facility with TPG Sixth Street Partners
4:08pm
8-K
EX-10.2
2q2a15eyihla4z
24 Feb 12
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
21t1f
14 Jan 20
Building the Premier Women’s Health Company JP Morgan Conference January 2020
6:55am
8-K
EX-99.1
pbpkkjbeue0cnmz7c zx
25 Sep 13
Therapeuticsmd Announces Pricing of Offering of Common Stock
12:00am
8-K
EX-99.1
84sn92 fi1784hgzq
2 Oct 18
Regulation FD Disclosure
7:00am
8-K
EX-10.09
qfyg7vsyjwb d33mp1
18 Feb 11
Entry into a Material Definitive Agreement
12:00am
8-K
4g1 kjto7du
25 Apr 19
TherapeuticsMD Closes $300 Million Non-Dilutive Term Loan Financing Facility
4:33pm
8-K
EX-99.2
6bnzdzsa4fle
13 Aug 18
TherapeuticsMDAnnounces FDA Approval of ANNOVERA ™(Segesterone Acetate/Ethinyl Estradiol Vaginal System) for Birth Control
6:01am
8-K
w08brp7ry
30 Dec 19
TherapeuticsMD Announces Amendment to
7:02am
8-K
EX-99.1
33wu70xtvw59ze
24 Sep 18
Regulation FD Disclosure
7:00am
8-K
EX-99.1
3mv2ufi
13 Nov 18
Regulation FD Disclosure
6:49am
8-K
EX-99.1
mmiu7mdn4t 4t
3 Mar 20
Regulation FD Disclosure
7:00am